Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 30.21
SGNT's Cash to Debt is ranked higher than
62% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. SGNT: 30.21 )
Ranked among companies with meaningful Cash to Debt only.
SGNT' s Cash to Debt Range Over the Past 10 Years
Min: 1.66  Med: 12.22 Max: No Debt
Current: 30.21
Equity to Asset 0.72
SGNT's Equity to Asset is ranked higher than
64% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. SGNT: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
SGNT' s Equity to Asset Range Over the Past 10 Years
Min: -1.15  Med: 0.67 Max: 0.77
Current: 0.72
-1.15
0.77
F-Score: 4
Z-Score: 2.77
M-Score: -2.47
WACC vs ROIC
15.15%
3.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -13.99
SGNT's Operating margin (%) is ranked lower than
81% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. SGNT: -13.99 )
Ranked among companies with meaningful Operating margin (%) only.
SGNT' s Operating margin (%) Range Over the Past 10 Years
Min: -258.05  Med: -14.11 Max: 12.82
Current: -13.99
-258.05
12.82
Net-margin (%) -6.87
SGNT's Net-margin (%) is ranked lower than
79% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. SGNT: -6.87 )
Ranked among companies with meaningful Net-margin (%) only.
SGNT' s Net-margin (%) Range Over the Past 10 Years
Min: -253.66  Med: -13.25 Max: 12.79
Current: -6.87
-253.66
12.79
ROE (%) -8.13
SGNT's ROE (%) is ranked lower than
76% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. SGNT: -8.13 )
Ranked among companies with meaningful ROE (%) only.
SGNT' s ROE (%) Range Over the Past 10 Years
Min: -26.08  Med: -8.34 Max: 16.09
Current: -8.13
-26.08
16.09
ROA (%) -5.91
SGNT's ROA (%) is ranked lower than
75% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. SGNT: -5.91 )
Ranked among companies with meaningful ROA (%) only.
SGNT' s ROA (%) Range Over the Past 10 Years
Min: -52.59  Med: -8.35 Max: 12.27
Current: -5.91
-52.59
12.27
ROC (Joel Greenblatt) (%) -42.18
SGNT's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. SGNT: -42.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGNT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -414  Med: -48.77 Max: 49.31
Current: -42.18
-414
49.31
Revenue Growth (3Y)(%) 14.40
SGNT's Revenue Growth (3Y)(%) is ranked higher than
75% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. SGNT: 14.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGNT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 5.20 Max: 46.4
Current: 14.4
0
46.4
EBITDA Growth (3Y)(%) 42.20
SGNT's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. SGNT: 42.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGNT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -43.70 Max: 42.2
Current: 42.2
0
42.2
EPS Growth (3Y)(%) 3.90
SGNT's EPS Growth (3Y)(%) is ranked lower than
56% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. SGNT: 3.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGNT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -35.00 Max: 3.9
Current: 3.9
0
3.9
» SGNT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SGNT Guru Trades in Q1 2015

George Soros 115,500 sh (New)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Paul Tudor Jones 11,900 sh (-55.76%)
NWQ Managers 72,373 sh (-86.23%)
» More
Q2 2015

SGNT Guru Trades in Q2 2015

Steven Cohen 244,900 sh (New)
Jim Simons 90,700 sh (New)
George Soros 347,200 sh (+200.61%)
Paul Tudor Jones 22,692 sh (+90.69%)
NWQ Managers Sold Out
» More
Q3 2015

SGNT Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
George Soros Sold Out
Jim Simons Sold Out
Steven Cohen 229,500 sh (-6.29%)
» More
Q4 2015

SGNT Guru Trades in Q4 2015

Paul Tudor Jones 25,829 sh (New)
Steven Cohen 191,600 sh (-16.51%)
» More
» Details

Insider Trades

Latest Guru Trades with SGNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 14.37
SGNT's Forward P/E is ranked higher than
52% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. SGNT: 14.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.52
SGNT's P/B is ranked higher than
74% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. SGNT: 1.52 )
Ranked among companies with meaningful P/B only.
SGNT' s P/B Range Over the Past 10 Years
Min: 1.52  Med: 3.28 Max: 5.06
Current: 1.52
1.52
5.06
P/S 1.18
SGNT's P/S is ranked higher than
77% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. SGNT: 1.18 )
Ranked among companies with meaningful P/S only.
SGNT' s P/S Range Over the Past 10 Years
Min: 0.46  Med: 2.46 Max: 3.86
Current: 1.18
0.46
3.86
Current Ratio 2.29
SGNT's Current Ratio is ranked lower than
53% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. SGNT: 2.29 )
Ranked among companies with meaningful Current Ratio only.
SGNT' s Current Ratio Range Over the Past 10 Years
Min: 1.57  Med: 2.34 Max: 3.71
Current: 2.29
1.57
3.71
Quick Ratio 1.38
SGNT's Quick Ratio is ranked lower than
64% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. SGNT: 1.38 )
Ranked among companies with meaningful Quick Ratio only.
SGNT' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 1.68 Max: 2.98
Current: 1.38
0.89
2.98
Days Inventory 110.11
SGNT's Days Inventory is ranked higher than
53% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. SGNT: 110.11 )
Ranked among companies with meaningful Days Inventory only.
SGNT' s Days Inventory Range Over the Past 10 Years
Min: 97.42  Med: 106.02 Max: 161.55
Current: 110.11
97.42
161.55
Days Sales Outstanding 58.97
SGNT's Days Sales Outstanding is ranked higher than
65% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. SGNT: 58.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGNT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.35  Med: 60.90 Max: 93.34
Current: 58.97
6.35
93.34
Days Payable 69.19
SGNT's Days Payable is ranked lower than
53% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. SGNT: 69.19 )
Ranked among companies with meaningful Days Payable only.
SGNT' s Days Payable Range Over the Past 10 Years
Min: 52.21  Med: 82.95 Max: 275.84
Current: 69.19
52.21
275.84

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.11
SGNT's Price/Net Current Asset Value is ranked higher than
71% of the 428 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.81 vs. SGNT: 4.11 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGNT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.23  Med: 5.24 Max: 10
Current: 4.11
4.23
10
Price/Tangible Book 2.21
SGNT's Price/Tangible Book is ranked higher than
67% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. SGNT: 2.21 )
Ranked among companies with meaningful Price/Tangible Book only.
SGNT' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.02  Med: 3.64 Max: 4.46
Current: 2.21
3.02
4.46
Price/Projected FCF 2.69
SGNT's Price/Projected FCF is ranked higher than
50% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. SGNT: 2.69 )
Ranked among companies with meaningful Price/Projected FCF only.
SGNT' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.67  Med: 3.67 Max: 3.67
Current: 2.69
Price/Median PS Value 0.48
SGNT's Price/Median PS Value is ranked higher than
91% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. SGNT: 0.48 )
Ranked among companies with meaningful Price/Median PS Value only.
SGNT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 1.00 Max: 1.23
Current: 0.48
0.43
1.23
Earnings Yield (Greenblatt) (%) -13.90
SGNT's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. SGNT: -13.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGNT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 1.60 Max: 7.5
Current: -13.9
0.3
7.5

More Statistics

Revenue(Mil) $318
EPS $ -0.67
Beta1.63
Short Percentage of Float13.69%
52-Week Range $11.36 - 26.47
Shares Outstanding(Mil)32.84

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 344 386 419
EPS($) 0.50 0.81 1.06
EPS without NRI($) 0.50 0.81 1.06

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:SZSE:300452, TSX:GUD, NAS:MNTA, NAS:SCLN, XKRX:001060, CAI:PHAR.CA » details
Traded in other countries:S06.Germany,
Sagent Pharmaceuticals Inc is a Delaware corporation that was incorporated in 2011. The Company was initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, it reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with its initial public offering, on April 26, 2011. The Company is engaged in the developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily in the United States of America. The Company primarily focuses on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, it offers customers, products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. It generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. At the year end, the Company's product portfolio has grown to a total of 53 products which can be classified into the following three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. The Company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by a wide variety of end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. The Company's principal competitors include Fresenius Kabi, a division of Fresenius SE, Hospira, Inc., Pfizer Inc., Sandoz International GmbH, a division of Novartis AG, Teva Pharmaceutical Industries Ltd. and West-Ward Pharmaceutical Corp. The Company is subject to extensive regulation by governmental authorities in the U.S. and in other countries.
» More Articles for SGNT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
ETF’s with exposure to Sagent Pharmaceuticals, Inc. : April 25, 2016 Apr 25 2016
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2016 Financial Results Apr 25 2016
Sagent Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SGNT-US :... Apr 22 2016
Stock Picking Strategy to Win Every Earnings Season Apr 12 2016
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 06 2016
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Mar 28 2016
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Mar 23 2016
Sagent Pharmaceuticals Names Sean Brynjelsen Executive Vice President, Business Development Mar 23 2016
Sagent Pharmaceuticals Names Sean Brynjelsen Executive Vice President, Business Development Mar 23 2016
SAGENT PHARMACEUTICALS, INC. Financials Mar 11 2016
SAGENT PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 07 2016
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection, USP, (in... Mar 01 2016
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Feb 25 2016
Sagent Pharmaceuticals Names Frank Harmon Executive Vice President Global Operations Feb 25 2016
Sagent Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : February 18,... Feb 18 2016
Sagent Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers Feb 17 2016
Edited Transcript of SGNT earnings conference call or presentation 16-Feb-16 2:00pm GMT Feb 16 2016
Sagent reports 4Q loss Feb 16 2016
Sagent reports 4Q loss Feb 16 2016
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK